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Abstract:
DCBLD2 is a scaffolding receptor possibly involved in neuronal migration or differentiation. It contains
seven intracellular tyrosine sites that can be phosphorylated to allow Crk/CrkL binding. Crk/CrkL are
involved in the Reelin signaling pathway that regulates neuronal migration in the developing cortex. My
research was aimed at understanding the subcellular localization of DCBLD2 and to determine if its
ability to become tyrosine phosphorylated altered its localization. I hypothesized that DCBLD2 would
localize similarly to NP1 and PlxnA2 based on their similar functions relayed to axon guidance and their
similar ectodomains. DCBLD2 is termed a neuropilin-like protein as they have similar ectodomains. NP1
is a co-receptor to PlxnA2 and together they respond to semaphorins to regulate axonal guidance.
Therefore, DCBLD2 might localize similarly to NP-1 and PlxnA2 within a cell. It is possible that the
mutant version of DCBLD2, lacking the seven tyrosine sites, will localize differently than the wild type,
perhaps driving it more or less towards the plasma membrane. I created three constructs to study
DCBLD2 in human embryonic kidney cells. These constructs were visualized via immunofluorescence.
From the images and statistical results, both DCBLD2 wild type and the phosphorylation site mutant
localize similarly to PlxnA2.
Abbreviations used: Crk – CT10 Regulator of Kinase, CrkL – Crk-like, SH2 – Src-Homology 2, SH3 –
Src Homology 3, SDS-PAGE – Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis, SFK – Src
Family Kinase, DCBLD – Discoidin, CUB, and LCCL Domain- Containing, NP1- Neuropilin 1, PlxnPlexin, Abl- Abelson Murine Leukemia Viral Oncogene Homolog 1, VEGF- Vascular Endothelial
Growth Factor, HEK – Human Embryonic Kidney, SILAC- Stable isotope labeling with amino acids in
cell culture
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Introduction
Neurons interact and respond to neighboring neurons to facilitate movement and signal transduction. The
neurons undergo neuronal migration by responding to cues that regulate their cytoskeleton
rearrangements. Neurons have a range of receptors on their cell membrane that receive signals and bind
them. They convert these signals into mechanisms called signal transduction pathways. These protein
receptors are important for cytoskeletal alterations that lead to neuronal migration. Neuropilins are a
family of co-receptors that along with Plexins aid in neuronal migration (Waimey, Huang, Chen, &
Cheng, 2008).
Neuronal migration is known to be governed by tyrosine kinases of the Src family (SFKs) in
collaboration with the adaptors Crk and CrkL (Tikhmyanova, Little, & Golemis, 2010). Together, they
control alterations in the cytoskeleton. SFKs phosphorylate protein substrates that then enable Crk and
CrkL to bind. Crk and CrkL carry with them associated proteins that regulate the cytoskeleton to
effectuate cellular migration.
A proteomics screen identified the transmembrane protein DCBLD2 as a substrate of SFKs that when
phosphorylated, promotes CrkL binding (Aten et al., 2013a). This suggests DCBLD2 could be a scaffold
to regulate neuronal migration. Furthermore, DCBLD2 has a structure similar to neuropilins, a family
known to critically regulate neuronal migration. DCBLD2 has seven intracellular tyrosine sites that when
phosphorylated by Fyn, other SFKs, or other tyrosine kinases leads to DCBLD2 binding to CrkL and then
potential alterations in the cytoskeleton leading to neuronal movement (Aten et al., 2013a).
Crk and CrkL were found to be essential in Reelin signaling during brain development. This pathway
controls the neural cell migration and proper patterning of several tissue types during embryonic
development. Reelin is also shown to effect neuronal migration in adult brains. Reelin assists in cellular
adhesion of cortical neurons lacking a radial scaffold (D’Arcangelo, 2014). Crk and CrkL were
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discovered as important adaptor proteins in this process (Ballif et al., 2004). Without Crk/CrkL the
cortical neurons’ Reelin pathway was disrupted and downstream effectors of Crk/CrkL were not
phosphorylated (Park & Curran, 2008). There is an unusual layering phenotype seen in the cortex when
Crk/CrkL cannot bind and aid in the Reelin pathway via Dab1 (L. Feng & Cooper, 2009). Since this
discovery, DCBLD2 was found to be a CrkL-SH2 binding partner via a proteomic screening. SFKs
induced DCBLD2 binding as seen via GST-CrkL-SH2 pulldown on DCBLD2 protein lysates (Aten et al.,
2013). DCBLD2 was then discovered to be a scaffolding receptor that controls VEGF-A-signaling
through the VEGFR-2 receptor. This controls angiogenesis (Kobuke et al., 2001). DCBLD2 may also
regulate neuronal differentiation or positioning in developing zebrafish (Joy, Wysolmerski, Ballif, &
Ebert, 2015).
A current model as to how DCBLD2 signaling might begin is through the clustering of DCBLD2 by
potential ligands and, thereby, leading to SFK activation and recruitment of Crk/CrkL to lead to changes
in migration (Figure 1).

Figure 1: Proposed mechanism of DCBLD2 acting as a scaffold for the CrkL adaptor protein.
DCBLD2’s ectodomains are clustered (done by unknown X/Y/Z factors). This enables low-activity SFKs
to come closer to each other and activate each other. DCBLD2 is a substrate of SFKs and other tyrosine
kinases at many tyrosine residues, which bind to the domains of the SFKs. DCBLD2’s phosphotyrosine
sites recruit CrkL and other proteins that could participate in the signaling. Figure adapted from: (Aten et
al., 2013).
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Receptors of various types are known to be continually trafficked to and away from the cell surface, with
phosphorylation leading to increased or decreased cell surface expression. Neuropilin has been shown to
be internalized after its co-receptor, the VEGFR receptor, is phosphorylated. When the phosphorylation is
blocked, both the VEGFR receptor and Nrp-1 are not internalized (Prahst et al., 2008). Another receptor,
EGFR, which binds epidermal growth factor is also internalized after it is phosphorylated to allow
continued signaling within the cell. Human papilloma virus proteins help with the internalization of the
EGFR to continue signaling and proliferation of cells (Shostak et al., 2014). In regards to PlexinA2, I
could not find evidence that it is internalized after phosphorylation normally. But, in Alzheimer’s mice,
Sema6A is internalized into vesicles within cortical pyramidal neurons. When the Sema6A is internalized,
the Neuropilin and PlxnA2 receptor complex is also internalized and the two proteins are then separated
in the cytoplasm (Good et al., 2004). It then gives the impression that PlxnA2 is either degraded or sent
back to the membrane, while the Neuropilin remains internalized within the cell. These three examples
show that tyrosine phosphorylated-mediated receptors do traffick to the membrane.
On the other hand, there are some proteins that upon phosphorylation are trafficked to the plasma
membrane. One example is aquaporin-2, which is phosphorylated by protein kinase A (PKA). PKA
phosphorylation targets and inserts aquaporin-2 in the plasma membrane. Another example is a potassium
voltage-gated channel called Kv1.2. Kv1.2 is trafficked to the surface of cells when it is phosphorylated
(Connors, Ballif, & Morielli, 2008). These two proteins reveal that tyrosine phosphorylation can also
cause protein trafficking to the membrane.
I hypothesize that the wild type DCBLD 2 will be trafficked normally to and away from the membrane,
similar to PlexinA2, a cell surface receptor important in guiding neurons during development (Waimey et
al., 2008). However, I hypothesize that the mutant version of DCBLD2, with phenylalanines replacing all
tyrosines in the motifs capable of recruiting Crk/CrkL, will have its localization to, or away from, the
membrane disrupted. Therefore, the mutant form of DCBLD2 is expected to be over- or under-expressed
at the membrane relative to wild type if trafficking away or to the membrane is disrupted respectively.
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My project primarily focuses on determining if DCBLD2 is similar to PlexinA2 in subcellular
localization. Additionally, understanding how the subcellular localization of these proteins compares to
that of other guidance receptors, most importantly NP1, which is a co-receptor with Plexins for binding to
Semaphorins. NP1’s ectodomain includes two CUB domains, one F5/F8 type C domain (Discoidin
domain), and one MAM domain (“NRP1 (human)” ). DCBLD proteins have one CUB domain, one F5/F8
domain, and one LCCL domain as seen in Figure 2. As these proteins share similar ectodomains and are
involved in similar biological functions, it might be expected that their subcellular localization will be
similar. For example, if DCBLD2 is to act as a guidance receptor, it would need to be able to bind
guidance cues in the extracellular space. However, if the intracellular domain is the important domain in
trafficking, then DCBLD2 and NP1 might not have a similar subcellular localization. Research is still
being done to see how protein localization is affected by the ecto and endodomains.
One paper found the ectodomains to be important in plasma membrane microdomain localization of the
tetherin protein. Certain mutations in the ectodomain made tetherin unable to be localized in the plasma
membrane or have the ability to release its particles (Hammonds et al., 2012). On the other hand, one
paper found the endodomain of p15 FAST protein to be important in targeting it to the plasma membrane.
They found that certain motifs on the endodomain interacted with other proteins to aid in the trafficking
towards the membrane (Top, Barry, Racine, Ellis, & Duncan, 2009). With these in mind, the ectodomain
may or may not be the main influence of DCBLD2 subcellular localization trafficking. But, the
ectodomains are shared between DCBLD2 and NP1, which could possibly lead to similar localization
patterns.
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Figure 2. NP-1 and DCBLD2 share similar ectodomain components. This is a model of DCBLD2’s,
PlxnA2’s, and Nrp-1’s protein ectodomains that were created using a protein scanner program against
known structural motifs. This shows that both DCBLD2 and NP-1 have CUB and FV/FVIII domains, and
therefore, might have a similar subcellular localization.
To study if DCBLD2 has a similar subcellular localization as neuropilin and Plexins, and to see if this
localization is regulated by tyrosine phosphorylation, I first needed to create DNA vector constructs
encoding tagged DCBLD proteins to assist in the visualization of DCBLD2 when transfected in cells. The
tagging allows for the cells to be viewed under a fluorescent microscope when stained with an antibody.
To do this, three DCBLD2 constructs were used and two of them I created. They include a Flag-tagged
fusion, an IRES-mCherry construct, and an mCherry-tagged fusion. These will be made for both the wild
type and mutant DCBLD2 (Y7F, all seven YxxP motifs in the intracellular domain mutated to FxxP).
These were transfected into cells and I used immunofluorescent techniques to follow their localization. As
controls, we have the same three aforementioned constructs for PlexinA2 for comparison.
The DCBLD2 Flag-tagged construct was purchased from Origene. The mutant (Y7F) Flag-tagged
construct was generated from the original WT construct by BioBasic. Therefore, they were ready to
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transfect into standard HEK293 cell lines, followed by an immunofluorescence protocol with an anti-Flag
antibody, and mounting onto slides to view under a confocal microscope.
The DCBLD2-IRES-mCherry construct was sub-cloned from the original Flag-tagged DCBLD2
construct. This DCBLD2-IRES-mCherry construct can be transfected into cells and the transfected cells
fluoresced red under the microscope without any immunofluorescent antibody-dependent procedure
needed. The IRES sequence is an internal ribosome entry site, which is where the ribosome attaches to
start translation of the sequence. The mCherry protein (encoded by a sequence of 711 base pairs) is what
fluoresces red when hit by an appropriate laser. This was viewed under the epi-fluorescent microscope
(“mCherry Sequence and Map”). If the cells were fluorescing red, this indicates that both the DCBLD2
and mCherry sequences were being translated as they were being generated from the same transcript.
The DCBLD2-mCherry fusion construct was sub-cloned using polymerase chain reaction and the original
DCBLD2 Flag-tagged construct. The PCR product was put into a different final vector (pCS2+) to enable
the creation of mRNA that can be injected into primary retinal ganglion cells. The DCBLD2-mCherry
fusion construct can be transfected into cells and can be directly visualized under the microscope like it
was with the IRES-mCherry construct. The mRNA collected in vitro will be sent to collaborators at
Boston College to be injected into frog zygotes. The embryos will grow/develop until the retinal ganglion
cells start to form (takes about 2-3 days), then the cells of the embryos will be disassociated and cultured.
The retinal ganglion cells will be viewed under the microscope to watch the changing localization of
DCBLD2 in living primary neural cells.
However, the data for this thesis involved transfecting the DCBLD2 constructs into HEK293 cells and
comparing them to similar PlexinA2 constructs to find out where the two proteins are located in their
static states. After determining the appropriate amount of DNA to use for the transfections, transfected
cells were stimulated or left untreated before subcellular localization was determined. In the stimulation
experiments, the constructs were transfected into cells just as they were for the static fluorescent imaging
and stimulated with hydrogen peroxide prior to mounting. Hydrogen Peroxide blocks tyrosine
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phosphatases allowing phosphotyrosine to accumulate on proteins in the cell from endogenous kinases.
Therefore, the hydrogen peroxide should increase the phosphorylation of DCBLD2 in the cells. These
phosphorylated forms might traffick the DCBLD2 towards or away from the membrane as
phosphorylation is an important mechanism whereby proteins normally are relocated within a cell (Chan
et al., 2012).
DCBLD2 is also known as ESDN (Endothelial and Smooth Muscle-derived neuropilin-like protein).
Therefore, it is expected that DCBLD2 might function and localize similarly to neuropilins. In past
research, Neuropilin has been found to localize to the cell membrane in immunofluorescent experiments
(Cariboni et al., 2007). Plexins are semaphorin-receptors that form a neuropilin-plexin complex (Renaud
et al., 2008). In past immunofluorescent experiments, plexins have been found to also localize to the cell
membrane (“anti-Plexin B2 antibody (AA 1-470, full length) | Product No. ABIN525353”). These results
led to my hypothesis that DCBLD2 has a similar subcellular localization and trafficking towards or away
from the cell membrane like neuropilin and plexin proteins.
The sub-cellular localization work will be helpful in ultimately determining its mechanism in neuronal
cells and other systems. This work is significant, because DCBLD2 is likely important in many signaling
mechanisms and cascades. Other than the neuronal network, DCBLD2 has been found to be involved in
vascular remodeling and growth. DCBLD2 upregulation increases vascular smooth muscle cell growth
(Guo et al., 2009). DCBLD2 has also been studied in zebrafish and has shown to be important in the
inhibition of thrombus formation (O’Connor et al., 2009) and eye development (Joy et al., 2015).
Morpholino-injected zebrafish with targets for platelet proteins showed that a DCBLD2 knockdown,
thrombus initiation and formation was interrupted. Phenotypic analysis of the zebrafish were carried out
to see the deleterious effects on thrombus formation by DCBLD2 (O’Connor et al., 2009).
Since the zebrafish genome is greatly homologous to the human genome (Howe et al., 2013), it can be
inferred that DCBLD2 could be involved in human eye and thrombus development too. Taking this into
consideration, DCBLD2 is involved in many different functions from development, growth, migration,
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and pathological functions. By finding the subcellular localization of DCBLD2 wild-type and the mutant,
I can determine how similar DCBLD2 is to neuropilin and plexins. This information will further our
understanding of DCBLD2 localization, how these proteins are trafficked when phosphorylated, and how
this new information plays a crucial role in the neuronal signaling pathways in which DCBLD2 is
involved.
Materials and Methods
I.

Making Constructs
A. DCBLD2 Flag-tagged Construct
DCBLD2 Flag-tagged construct was purchased from Origene. The mutant Y7F Flagtagged construct was generated from the original WT by BioBasic.
B. DCBLD2-IRES-mCherry Construct
I needed to replace PlxnA2 DNA with DCBLD2 WT and Y7F sequence from a
PlxnA2-IRES-mCherry pCMV6 vector.
I achieved this goal by digesting PlxnA2-IRES-mCherry pCMV6 vector and
DCBLD2 Flag-tagged pCMV6 vector using the restriction enzymes: AsiSI and MluI.
The restriction enzyme AflII was also added to the PlxnA2-IRES-mCherry pCMV6
vector digest to further separate the IRES-mCherry pCMV6 vector from the PlxnA2
DNA sequence. 10X Cut-smart buffer was used in the digest reaction. The digest ran
overnight at 37°C. Then, I CIP treated the PlxnA2-IRES-mCherry pCMV6 vector
digest for 30 minutes at 37°C. CIP treatments causes the de-phosphorylation of 5’
and 3’ ends of DNA to allow ligation of sub-cloning DNA sequences.
Simultaneously, the DCBLD2 Flag-tagged digest was placed in a 4°C refrigerator.
Both digests were then heat-inactivated at 70°C for 20 minutes.
The digests were run on an agarose gel with a 1 kb ladder and uncut controls of each
vector at 130 V for 45 minutes. The DCBLD2 DNA band and IRES-mCherry
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pCMV6 vector bands were cut out of the gel using UV fluorescence. The gel was
then imaged. The two extracted bands were purified using the NucleoSpin kit.
These purified extracts were then ligated together using tDNA4 ligase and 2X quick
ligase buffer in a 3:1 vector (IRES-mCherry pCMV6) :insert ratio (DCBLD2). The
ligation took place overnight at room temperature. The controls were: insert alone
and vector alone tubes. The three ligation tubes underwent bacterial transformation
and were plated on Kanamycin agar plates(“Addgene: Protocol - How to do a
Bacterial Transformation,” n.d.).
The next morning, five well isolated colonies from the ligation plate and one colony
from the vector alone ligation were grown up in 3 mL of LB Kanamycin Broth
overnight while shaking at 37°C. Minipreps were performed on the multiple samples
the next morning (“GenCatch Plasmid DNA Miniprep Kit,” 2010). The minipreps’
DNA quality was assessed by a spectrophotometer.
Then, the samples were digested/test-cut using AsiSI and MluI restriction enzymes
like with the first digest, heat-inactivated, and run on an agarose gel to test the
accuracy of the constructs.
C. DCBLD2-mCherry Fusion Construct
For the mCherry fusion construct, I needed to insert mCherry DNA into the DCBLD2
WT and Y7F Flag-tagged pCMV6 vector. Then to take the DCBLD2 mCherry DNA
sequence out of the pCMV6 vector and put it into an empty pCS2+ vector that easily
make RNA.
This was obtained using a similar sub-cloning procedure, but required ordering PCR
forward and reverse primers for the mCherry sequence, which is in the Supplemental
data. The PCR product was then run an agarose gel and purified.
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Then, the DCBLD2 Flag-tagged pCMV6 vector and PCR product were digested with
MluI and PmeI restriction enzymes for one hour at 37°C. The pCMV6 vector was CIPtreated for 20 minutes, then heat-inactivated, and then the digests were run on an agarose
gel. The appropriate bands were extracted and purified (mCherry sequence and DCBLD2
Flag-tagged pCMV6 vector). The vectors were then ligated, transformed, plated, miniprepped, and test-cuts were run (using EcoR1 and XbaI restriction enzymes) as before.
The ligated DCBLD2 mCherry fusion construct and an empty pCS2+ vector were
digested using EcoR1-HF and Xba1 for one hour at 37°C. Then, the pCS2+ was CIP
treated for 20 minutes, both tubes were heat inactivated, and then run on an agarose gel.
The appropriate bands were extracted (DCBLD2 mCherry sequence and pCS2+ vector)
and purified. The segments were then ligated, transformed, mini-prepped, and test cuts
were run for accuracy. I had assistance from Riley St. Clair in making the DCBLD2 WT
mCherry fusion construct.
This final DCBLD2 mCherry fusion construct was used to make mRNA. The mRNA
collected in vitro will be sent to collaborators at Boston College to be injected into frog
zygotes. The embryos will grow/develop until the retinal ganglion cells start to form
(takes about 2-3 days), then the cells of the embryos will be disassociated and cultured.
The retinal ganglion cells will be viewed under the microscope to watch the changing
localization of DCBLD1 and 2 in living primary neural cells.
II.

Immunofluorescent Microscopy Set-up
A. DCBLD2 Flag-tagged Immunofluorescence
The DNA was transfected (from 0.025 to 2.5 ug titer) into HEK293 cells (in a 6 well-dish
with coverslips) (“Calcium Phosphate Transfection Kit - Thermo Fisher Scientific,” n.d.).
The cells were incubated for six hours at 37°C, rinsed with fresh media, and incubated
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again overnight. The media was aspirated, then 1 mL of fixative was added (3.7%
Paraformaldehyde in 1X PBS) to each well for 10 minutes at room temperature. The
fixative was aspirated off, the cells were then rinsed with 1 mL of 1X PBS, aspirated
again, and 1 mL of Permeant (1.2 mL 10X PBS, 300 uL 20% Triton, and 10.5mL
distilled water) was added for 10 minutes at room temperature.
The permeant was aspirated off, rinsed with 1X PBS, aspirated, 1 mL of Blocking
solution (1.5 mL BSA in PBS) was added, and left to sit at room temperature for one
hour. The blocking solution was aspirated off, then 1 mL of primary antibody solution
(1:5000 mouse anti-Flag in 1.5% BSA in PBS) was added. The 6-well dish was placed in
a moist environment (plastic container with wet paper towel) and it rocked at room
temperature for one hour. The primary antibody was aspirated off and 1 mL of secondary
antibody solution (1:10,000 anti-mouse 488-Green in 2% BSA in PBS) was added. The
dish was kept in a moist environment and it rocked for one hour at 4°C.
The secondary antibody was aspirated off and the cells were rinsed four times with 1X
PBS for five minutes with rocking (no container). The PBS was aspirated off and 1 mL of
distilled water was added. Coverslips were mounted on microscope slides using
VectaShield Hard Mount with DAPI. The microscope slides were stored at 4 degrees
Celsius in the dark and imaged using a confocal microscope.
B. DCBLD2 mCherry Fusion Constructs Static Immunofluorescence
The DNA was transfected (from 0.025 to 2.5 ug titer) into HEK293 cells (in 6 welleddishes with coverslips) (“Calcium Phosphate Transfection Kit - Thermo Fisher
Scientific”). The cells were incubated overnight at 37°C, rinsed, and fresh media was
added in the morning. In the evening, they were rinsed, starvation media was added, and
they were incubated again overnight.
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The media was aspirated off while on ice and three quick 1 mL 1X PBS washes were
performed. The PBS was aspirated off and 1 mL of fixative (3.7% Paraformaldehyde in
1X PBS) was added to each well for 10 minutes at room temperature. The fixative was
aspirated off, one quick 1X PBS wash was performed, then aspirated off, and then 1 mL
of distilled water was added to each well. The coverslips were mounted on slides same as
previously stated.
C. DCBLD2 mCherry Fusion Constructs Stimulated Immunofluorescence
The same protocols for transfection, rinsing, and incubating as those for static
immunofluorescence were carried out; however, before the cells were put in fixative, they
were stimulated with 30 uL diluted hydrogen peroxide (10% hydrogen peroxide in water)
for 5, 10, or 20 minutes. The control had 30 uL of distilled water added into the other
wells. Then, the cells were put on ice, fixed, rinsed, and mounted as they were for the
static immunofluorescence.
III.

Immunofluorescent Microscopy Imaging
A. A confocal microscope with Nikon NIS Elements software imaging program was utilized
for imaging. I focused on the z focal plane near the middle of each cell. Images were
captured at 80x.
B. The confocal microscope was also used to take five stacked images of DCBLD2mCherry fusion WT cells as a control to show that all of my previously collected images
were actually in the middle of the cell. Each cell was around 6 microns thick. The zstacks were taken at 0.6 micron slices. Therefore, there were approximately 10 stacked
images taken of each cell.
C. ImageJ and Photoshop were used for immunofluorescent image production. I used
ImageJ to convert the NIS elements images into jpeg format. Then I used Photoshop to
superimpose the images (DAPI stained and mCherry fluorescent separate images).
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IV.

Data Analysis
A. ImageJ was used to measure the fluorescence intensity of the mCherry across each cell.
The ROI manager and line drawing tools were used to draw a line from one end of the
cell to the other end. The “analyze and graph” functions were used to give data values of
the fluorescence intensity versus distance across the cells. Then this same line was
shortened using the DAPI image to only encompass the nucleus portion of the fluorescent
DCBLD2 mCherry protein.
B. Excel was used to gather and store the data from thirty WT and thirty Y7F cells. Excel
subtracted the background fluorescence (about 30 fluorescent intensity units from each
data point). Then, all of the cells were made the same length by making the lengths out of
100% across the cells, and then converting the percentages into a final length of 16
microns. Then, all of the fluorescence values were normalized to be out of 100% for each
cell. The same procedure was carried out for the PlexinA2 images I received from Riley
St. Clair.
C. JMP Pro 13 and GraphPad Prism were used to upload, graph, and analyze all data points.
The mean and standard deviation values for the cells were utilized to construct an x vs y
graph. GraphPad Prism was used to further analyze the data using t-tests and testing if
curves were statistically significantly different from one another (for DCBLD2 WT vs.
Y7F and DCBLD2 vs. PlxnA2 WT).
D. Desmos Graphing Program was used to graph the three quadratic fitted equations on one
graph. (DCBLD2 WT, DCBLD2 Y7F, and PlexinA2 WT). It was also used to graph the
quadratic best-fit lines for the DCBLD2 WT and Y7F stimulation experiments.

Results:
To predict where DCBLD2 might be located within cells, I first used different computer algorithm
programs. The different protein localization programs were used to forecast if DCBLD2 had similar
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subcellular localization to NP1 and PlxnA2. The computer algorithm programs calculated the probability
of the proteins containing signal peptides, transmembrane helices, if it is targeted to the nucleus,
endoplasmic reticulum, mitochondria, cytoplasm, or if it is possibly secreted. Many control proteins were
used to test the accuracy of the programs. The controls were: mitochondrial calcium uniporter located in
the mitochondria, the insulin receptor in the plasma membrane, the binding immunoglobulin protein
located in the endoplasmic reticulum, lamin B receptor in the nuclear membrane, rhodopsin that is a
transmembrane protein, and tubulin in the cytoplasm. The results of all of the programs are in Table 1.
Immunofluorescent images of each protein tested in the programs are in Figure 3.

Table 1. The data predict DCBLD2, PlxnA2, and NP1 to have similar subcellular
localizations. The prediction programs I used were based on computer algorithms searching for
signal peptide sequences (Lukas Kall, et al., 2007 and Thomas Nordahl Petersen, et al., 2011),
transmembrane helices (Erik L.L. Sonnhammer, et al., 1998), nuclear targeting (Blum, T., et al.,
2009), endoplasmic reticulum targeting (Sigrist CJA, et al., 2012), mitochondrial residence
(M.G. Claros), cytoplasmic targeting (Sebastian Briesemeister, et al., 2010), secretion targeting
(D. Baú, et al., 2006), and an overall subcellular localization prediction (Olof Emanuelsson, et
al., 2000).

Signal Peptide
Transmembrane
Helices
Nuclear
Endoplasmic
Reticulum
Mitochondrial
Probability

DCBLD2

PlxnA2

NP-1

Mitochondrial
calcium
uniporter

X
X
X

X

X

X

X
X
X

1%

7%

1%

2%

Insulin
receptor

Binding
immunoglobulin
protein

X
X
X

X
X

12%

9%

Lamin B
receptor

Rhodopsin

Tubulin

X

X

36%

22%

16%

1.75%

6.76%

X
0.40%

Cytoplasmic

4.49%

5.26%

96.19%

X

6.10%

4.06%

13.56%

X

X

X

Secretion

X

X

X

X

X

Prediction (ER,
Mit, Other)

ER (99%)

Mit
(26%)

ER
(99%)

Mit (67%)

ER
(99%)

X
X

ER (99%)

other

other

other
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Figure 3. The locations of the aforementioned proteins based on immunofluorescence
matched the computer algorithm-based localization predictions. These proteins were: Plexin
A2 (A) (“Plexin A2 Antibody [Unconjugated] (AF5486): Novus Biologicals”), Neuropilin-1 (B)
(“Anti-Neuropilin 1 antibody [EPR3113] (ab81321) | Abcam”), Mitochondrial calcium uniporter
(C) (“Anti-MCU antibody (ab121499) | Abcam”), Insulin receptor (D) (“Anti-Insulin Receptor
antibody (ab5500) | Abcam”), Binding immunoglobulin protein (BiP) (E) (“Anti-GRP78 BiP
antibody (ab21685) | Abcam”), Lamin B receptor (F) (“Lamin B Receptor Antibodies: Novus
Biologicals”), Rhodopsin (G) (“Rhodopsin Antibody (RET-P1) (NB120-3267): Novus
Biologicals”), and tubulin (H) (“Anti-alpha Tubulin antibody (ab18251) | Abcam”). In A and B,
the proteins were visualized via antibodies conjugated to a red fluorophore, while C-H used a
green fluorophore conjugate. The blue DAPI stained the nucleus in all images. The red
phalloidin in C, F, and G stained the actin.

The results of the program predicted that DCBLD2 has a signal peptide (Figure 4), has transmembrane
helices (Figure 5), and has the ability to be near the cell membrane (secretion test). Different algorithm
programs calculated the transmembrane domain of the proteins and the cytoplasmic vs extracellular
portions of the proteins as seen in Figures 4 and 5. Both programs showed that DCBLD2, PlxnA2, and
NP-1 have a transmembrane domain, and are, therefore, most likely located in a membrane. With the
second program, the hydrophobic signal sequence was only seen as a small blip on the PlxnA2 and NP-1
compared to the first program used. This can be due to the first program specifically looking for signal
sequences, while the second program examined transmembrane domains. Since both contained
hydrophobic resides, the signal sequences would appear as small, possible transmembrane domains. Both
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programs predict the transmembrane domain to be in the same location for each individual protein. The
locations of the transmembrane domains differed for the three proteins based on how long the peptide
sequences were and where they were located. The data from the prediction programs coincide with my
main hypothesis that DCBLD2 was most likely located at the cellular membrane similarly to NP-1 and
PlxnA2.
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DCBLD2

PlxnA2

Nrp-1

Figure 4. Predicted locations of possible signal peptides within DCBLD2, PlxnA2, and NP1.
The red line to the left represented the signal peptide (calculated using a program to find signal
peptide cleavage sites and hydrophobic residues). It also showed transmembrane domains in gray
via hydrophobic residues and possible alpha helix forming amino acid sequences. It predicts that
DCBLD2’s transmembrane domain is about 500 amino acids into the protein, PlxnA2’s is
around 1200 amino acids into the protein, and NP-1’s is approximately 880 amino acids in.
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DCBLD2

PlxnA2

Nrp-1

Figure 5. A model of the possible locations of transmembrane domains of DCBLD2,
PlxnA2, and NP1. It was calculated using a program that calculated the probability of having an
inside and outside helix domain. This revealed that all three proteins have transmembrane
helices. PlxnA2 and NP-1 show smaller red bars in the beginning, which are most likely the
hydrophobic residues of the signal peptide.
After taking into account the bioinformatics data, I needed to experimentally test the subcellular
localization of PlxnA2 and DCBLD2. To experimentally test the localization of the proteins, I needed to
create constructs that could be viewed via immunofluorescence under the microscope. The first constructs
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were DCBLD2 WT and Y7F Flag-tagged pCMV6 vectors that were already created. These were used to
create two more DCBLD2 constructs, which were the untagged DCBLD2 IRES-mCherry and DCBLD2
mCherry-fusion constructs.
The untagged DCBLD2 WT and Y7F IRES-mCherry constructs were useful for tracking whether
DCBLD2 was transfected into cells. In the Flag-tagged DCBLD2 constructs, there was no way to know,
by just looking at the cells under the microscope, the percentage that were successfully transfected. The
IRES-mCherry is a protein with its own internal ribosomal entry site, so that it can be transcribed into the
mCherry protein. The IRES-mCherry sequence lies upstream of the DCBLD2 gene, so if the mCherry
was transcribed, then the DCBLD2 was most likely being transcribed too. This made cell-to-cell
comparisons easier based on transfection status. If the transfection was successful in a cell, the cell would
appear red when hit with the appropriate wavelength of light. This allowed direct comparison of cells
with the mCherry and DCBLD2 expressing to surrounding cells that were unsuccessful in transfection.
The plan to create the IRES-mCherry constructs is seen in Figure 6. After the initial digest of the
DCBLD2 pCMV6 and PlxnA2-IRES-mCherry pCMV6 constructs, the gel was imaged after extraction in
Figure 7 and 9. Then, the ligation, bacterial transformation, and purification of plasmid led to the test cuts
of the new DCBLD2 IRES-mCherry constructs in Figure 8 and 10. The test cuts revealed all purified
plasmids had the appropriate sized DCBLD2 inserts. To further test the accuracy of these constructs, I
used immunofluorescence and Western blots. Immunflourescence showed if the IRES-mCherry was
expressing, if so, DCBLD2 was most likely be expressing as well (Figure 11). Western blots tested if the
transfected cells were transcribing and translating DCBLD2 (Figures 12 and 13).
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Figure 6. Cloning strategy representing how the ESDN WT and Y7F IRES-mCherry vector
constructs were created. The final construct was constructed from PlxnA2 WT IRES-mCherry pCMV6
and DCBLD2 WT/Y7F pCMV6 entry vectors.
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Figure 7. Restriction enzyme digests separated into DCBLD2 WT sequence and IRES-mCherry
vector enabling them to be ligated together. The agarose gel shows the digested bands that were cut out
and used for the IRES-mCherry WT construct ligation. DCBLD2 WT Flag-tagged pCMV6 vector and
PlxnA2 IRES-mCherry pCMV6 vector were digested with AsiSI and Mlu I (and AflII for the Plxn digest
tube). The black cutouts show the two bands I extracted were the DCBLD2 band (expected length: 2.3
kb) and the IRES-mCherry pCMV6 vector band (expected length: 6.2 kb).
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Figure 8. Restriction enzyme test-cuts showed successful creation of the DCBLD2 WT IRESmCherry construct. The test-cuts with AsiSI and Mlu I reveal the appropriate band sizes. The bands
with arrows are as follows: the DCBLD2 band (expected length: 2.3 kb) and the IRES-mCherry pCMV6
vector band (expected length: 6.2 kb). The PlxnA2 IRES-mCherry pCMV6 digest produces two bands
that are close in size, hence why they appear to be one large band (**). The IRES-mCherry vector alone
ligation digest reveals a protein that looks uncut (***). And the largest band in the DCBLD2 WT pCMV6
digest lane represents a non-supercoiled, uncut band that may be nicked (*).
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Figure 9. Restriction enzyme digests separated into DCBLD2 Y7F sequence and IRES-mCherry
vector to enable their ligation. The agarose gel shows the bands that were cut out and used for the
DCBLD2 Y7F IRES-mCherry construct ligation. DCBLD2 Y7F Flag-tagged pCMV6 vector and PlxnA2
IRES-mCherry pCMV6 vector digest with AsiSI and Mlu I (and AflII for the Plxn digest tube). The black
cutouts show the two bands I extracted were the DCBLD2 Y7F band (expected length: 2.3 kb) and the
IRES-mCherry pCMV6 vector band (expected length: 6.2 kb).

Figure 10. Figure 8. Restriction enzyme test-cuts showed successful creation of the DCBLD2 Y7F
IRES-mCherry construct. The test-cuts with AsiSI and Mlu I reveal the appropriately sized expected
bands. The bands with arrows are as follows: the DCBLD2 Y7F band (expected length: 2.3 kb) and the
IRES-mCherry pCMV6 vector band (expected length: 6.2 kb).
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Figure 11. mCherry expression in HEK293 cells from the IRES-mCherry constructs implied that
DCBLD2 was also being expressed. A. DCBLD2 wild-type IRES-mCherry vector transfected into
HEK293 cells. B. DCBLD2 Y7F mutant IRES-mCherry vector transfected into HEK293 cells. C. Bright
field image shows the HEK293 cells size and shape. This is correlated with figure D (a close-up of Figure
11A) to see differences in morphology based on whether the cells took up the plasmid or not.

Figure 12. DCBLD2 was being expressed in HEK293 cells transfected with DCBLD2 WT IRESmCherry. The western blot was created from a test transfection using the DCBLD2 WT IRES-mCherry
construct. An anti-DCBLD2 primary antibody and anti-rabbit secondary antibody were used. The
expected molecular weight of DCBLD2 is 120 kDa. The five DCBLD2 WT IRES-mCherry colonies were
generated from the ligation colonies seen in Figure 8.
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Figure 13. Figure 12. DCBLD2 was being expressed in HEK293 cells transfected with DCBLD2 Y7F
IRES-mCherry. A western blot created from a test transfection using the DCBLD2 Y7F IRES-mCherry
construct. An anti-DCBLD2 antibody was used. The expected molecular weight of DCBLD2 is 120 kDa.
The five DCBLD2 Y7F IRES-mCherry colonies are generated from the ligation colonies seen in Figure
10. Unexpectedly, the mock transfection (Mock) shows a light band that is expected contamination from
an unknown source. PlxnA2 negative control comparison still shows that the five DCBLD2 Y7F IRESmCherry clones were expressing DCBLD2. (*)
As discussed above, the next step was to create DCBLD2 mCherry-fusion constructs. The fusion
constructs would link the mCherry to the DCBLD2 protein, unlike the IRES-mCherry constructs where
the DCBLD2 and mCherry were separate proteins. The mCherry-fusion constructs allowed the
visualization of DCBLD2’s and PlxnA2’s localization in cells. To sub-clone the DCBLD2 WT and Y7F
mCherry-fusion constructs, the plan seen in Figure 14 was used. The same protocols and accuracy tests
were performed on these created constructs that were used for the IRES-mCherry constructs. The gels are
not shown, because Riley St. Clair finished creating the mCherry fusion constructs by placing the
DCBLD2 mCherry sequence into the final pCS2+ vector.
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Figure 14. Cloning strategy representing how to create the ESDN WT and Y7F mCherry fusion
vector constructs.
The mCherry fusion constructs were used to test the subcellular localization of DCBLD2. I used the
DCBLD2 mCherry fusion construct still in the pCMV6 vector to transfect into the HEK293 cells while
Riley finished sub-cloning the sequence into the pCS2+ vector. The Flag-tagged and mCherry fusion
constructs were both visualized via immunofluorescent procedures using HEK293 cells and confocal
microscopy. The Flag-tagged DCBLD2 constructs were imaged first because the other DCBLD2
constructs (IRES-mCherry and mCherry fusion) were still being created.
In the original DCBLD2 Flag-tagged images I captured (Figure 15), the DCBLD2 protein does appear to
localize to the plasma membrane in both the wild-type and mutant constructs. The initial images were
weak with the Flag-tagged DCBLD2 construct, which could be corrected by procedure. The Flag-tagged
constructs involved fixing cells; therefore, the mCherry fusion constructs were needed for live cell
imaging, which could perhaps could give a stronger immunofluorescent signal than the Flag-tagged
constructs.
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Figure 15. Representative images of anti-Flag (conjugated to a green fluorophore) mediated
immunofluorescence show plasma membrane and cytoplasmic subcellular localization of DCBLD2.
A-C DCBLD2 wild-type pCMV6 vector transfection of HEK293 cells. D-F DCBLD2 Y7F mutant DNA
in pCMV6 vector transfection of HEK293 cells.
Simultaneous to the DCBLD2 Flag-tagged immunofluorescent protocol, the PlxnA2 Flag-tagged
procedure was performed by Riley St. Clair. The PlxnA2 Flag-tagged images can be seen in Figure 16.
PlxnA2 shows a similar localization to that of DCBLD2. Both proteins look to be nearer to the plasma
membrane and have some cytoplasmic presence. These PlxnA2 data were compared to the DCBLD2 data.
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Figure 16. PlxnA2 WT revealed similar subcellular localization patterning to DCBLD2 WT. These
immunofluorescent images of PlxnA2 WT Flag-tagged constructs in HEK293 cells were obtained from
Riley St. Clair. The right four images are zoomed-in images of the left four. The blue represents DAPI
staining of DNA in the nucleus. The green shows the conjugated green fluorophore to the anti-Flag
antibody.
After the mCherry-fusion constructs were created, they were transfected into cells. The cells were fixed
and mounted onto slides similarly to the Flag-tagged constructs. The cells used were in a static state and
no molecule was added that would increase phosphorylation. These images captured the natural state of
DCBLD2 in cells when they are minimally phosphorylated.
The static images of the mCherry fusion constructs in Figure 17 showed DCBLD2 around the cell
membrane, but also at other intracellular/cytpolasmic locations. Also seen here, there appeared to be little
difference between the wild-type and mutant constructs. The visual conclusion that was drawn is that
DCBLD2 was localized near the membrane when it was not phosphorylated.
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Figure 17. The DCBLD2 mCherry fusion construct exposes similar subcellular localization between
DCBLD2 WT and Y7F. A-C DCBLD2 mcherry DNA in pCMV6 vector transfected into fixed HEK293
cells. D-F DCBLD2 Y7F mutant mcherry DNA in pCMV6 vector transfected into fixed HEK293 cells.
The right six images are zoomed-in versions of the left six images.
After seeing the results of un-phosphorylated DCBLD2, I wanted to see if phosphorylation was able to
change the localization of the protein. To test this, the stimulation experiments with hydrogen peroxide
for different lengths of time (5, 10, and 20 minutes). This would reveal if possibly increasing the
phosphorylation of DCBLD2 (Aten et al., 2013) changes the overall localization.
The stimulated mCherry constructs in Figure 18 showed DCBLD2 localization does not look like it was
affected by stimulation via hydrogen peroxide. Both the wild-type and Y7F constructs were seen in
similar locations as they were in the un-stimulated cells. DCBLD2 was, in all cases, seen mostly at the
cell membrane, but also loosely throughout the cytoplasm of the cells. However these qualitative
assessments needed statistical analysis to further evaluate if DCBLD2 was localized at the plasma
membrane and if phosphorylation changed this localization.
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Figure 18. Hydrogen Peroxide stimulation did not visually affect subcellular localization of
DCBLD2. DCBLD2 mcherry DNA in pCMV6 vector was transfected into HEK293 cells. The left side
are the wild-type DCBLD2 cells and the right side show the DCBLD2 Y7F mutant expressing cells. The
different time points are listed to the left of the images (5, 10, or 20 minutes) and if the cells were
stimulated with hydrogen peroxide it is so indicated (+/-).
For a more thorough analysis of the subcellular localization, I first graphed all raw values from thirty cells
into a plot as seen in Figure 19. This plot was extremely unhelpful with such large standard deviations.
The issues were different lengths and fluorescence intensities of each cell. The cell lengths ranged from 6
to 24 microns. There were only a few cells that were 6 microns long; these cells were likely preparing for
cell division. Most of the cells were within a thinner range from 12 to 20 microns. The intensities ranged
from 200 to 3000 fluorescent intensity units. These caused the plot to have large standard deviations. I
decided this would not work, so I then graphed just the first half of the data points to try to make up for
the varying cell lengths (Figure 20) and I also tried to use only cells of one length (I chose an arbitrary
length of 15 microns) (Figure 21).
These also proved to not be helpful, because there was still a large intensity variation. Therefore, a new
approach was needed. The difference in cell lengths was difficult to overlook and skewed the plots. This
meant that, if DCBLD2 is localized around the membrane, it will peak at 0 and 6 microns for the short
cells but at 0 and 24 for the larger cells. This created an uneven graph. Next, I shrank/stretched each cell
to 16 microns long to avoid this problem. I also knew that with an intensity range from 200-3000 intensity
units for maximum values for each cell; therefore, I made the intensity values out of 100% for each

33
individual cell. So that peak intensity could still be measured across the cells and could be compared to
the other cells.

Figure 19. The plot vaguely shows plasma membrane localization of DCBLD2 WT by
increased fluorescence at both sides of cells. This is clouded by large standard deviations.
The plot was constructed with 30 DCBLD2 WT cells distance versus intensity with a line that
fits to the mean intensity at every 0.5 microns with large standard deviation error bars.
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Figure 20. The plot representing only half of the cell does not reveal plasma membrane
localization. This lack of localization determination is due to large standard deviations. The
plot consisted of 30 DCBLD2 WT cells distance versus intensity with a line that fits to the
mean intensity at every 0.5 microns with standard deviation error bars. This is plotting only
up to 8 microns length (about half of each cell) compared to almost full length in Figure 19.
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Figure 21. The plot is more symmetrical for plasma membrane localization, but still
contains large standard deviations. The plot only shows 5 DCBLD2 WT cells distance
versus intensity with a line that fits to the mean intensity at every 0.25 microns with standard
deviation error bars. This is plotting only cells that are 15 microns long taken from the data
used in Figure 19.

With the corrections to make size and intensity fluorescence comparable, Figures 22 and 23 were created
for both DCBLD2 WT and Y7F cells. All the cells used for this graph were between 12 and 20 microns
long. I also took into account the nucleus with these graphs. DCBLD2 is not known to or shown to be
bound or targeted to the nucleus via the prediction programs. Therefore, if I specifically looked at full cell
length intensities and intensities just in the nucleus, I should have seen little to no fluorescence of the
DCBLD2-fusion mCherry in the nuclear region of the cells.
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Figure 22. DCBLD2 WT mCherry fusion proteins shows membrane localization. The
plot of 30 DCBLD2 WT cells tells us that the DCBLD2 WT mCherry fusion protein appears
to be located at the plasma membrane. The graph plots distance versus intensity with a line
that fits to the mean intensity every 0.25 microns with standard deviation error bars. The red
points symbolize the area outside of the nucleus, while the black points represent the
mCherry fluorescence seen across the nucleus. The bottom two plots are breaking up the full
cell measurement and the across the nucleus measurement to show that there is very little
DCBLD2 mCherry fusion presence in the nuclear region.
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Figure 23. DCBLD2 WT and Y7F appear to have similar localizations. The plot of 30 DCBLD2 Y7F
mCherry fusion transfected cells looks very similar to the WT cells in Figure 22. The graph plots distance
versus intensity with a line that fits to the mean intensity every 0.25 microns with standard deviation error
bars. The red points symbolize the fluorescence seen outside of the nuclear region, while the black points
represent the fluorescence across the nucleus. The bottom two plots are breaking up the full cell
measurement and the across the nucleus measurement.
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Figures 22 and 23 both show DCBLD2-mCherry fluorescence to be gathered at the membrane as seen via
the peaks of fluorescence near both ends of the x-axis. The fluorescence was around 20% in the nuclear
region compared to 60% at the cell membrane. To note, the beginning and ending points of the lines
drawn were taken just outside of what I assumed to be the cellular plasma membrane for each cell.
Comparing the WT and Y7F DCBLD2 localization was difficult, because there was very little difference
seen between the two graphs or between the immunofluorescent images themselves.
My goal was to determine if the subcellular localization of DCBLD2 was similar in sub-cellular
localization to both PlexinA2 and Neuropilin-1. Riley St. Clair works with PlexinA2 and provided me
with her PlxnA2 WT Flag-tagged immunofluorescent images. These images were used to construct a
similar graph, which showed the relative intensity (Figure 24). All of the DCBLD2 and PlxnA2
subcellular localization graphs looked incredibly similar. PlexinA2 WT peaked around 55% intensity at
the membrane and bottomed out at 15% intensity in the nuclear region. The overall shape and slopes of
the plots for DCBLD2 WT and PlxnA2 WT appeared similar.
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Figure 24. PlxnA2 WT and DCBLD2 WT show similar subcellular localizations. The plot of 22
PlexinA2 WT Flag-tagged transfected cells looks similar to the DCBLD2 WT mCherry-fusion construct
transfected cells in Figure 22. The graph plots distance versus intensity with a line that fits to the mean
intensity every 0.25 microns with standard deviation error bars. The red points symbolize the fluorescence
outside of the nuclear region, while the black points represent the fluorescence across the nucleus.
The last goal was to see how stimulation via hydrogen peroxide affected the subcellular localization of
both DCBLD2 WT and Y7F (Figure 25). These plots were not as smooth or well-defined as the static
immunofluorescent plots. The hydrogen peroxide stimulated cells compared to the non-stimulated cells
showed no clear visual difference. Also, there were no glaring differences between the localization of the
DCBLD2 WT or Y7F cells again whether they were stimulated with hydrogen peroxide or not.
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Figure 25. Phosphorylation by hydrogen peroxide did not reveal localization differences in
DCBLD2. The plots of 10 DCBLD2-mCherry fusion WT and Y7F transfected cells show that
phosphorylation by hydrogen peroxide does not appear to affect the localization of DCBLD2. The plots
were distance versus intensity with a line that fits to the mean with standard deviation error bars. The red
points symbolize the outside the nucleus fluorescence, while the black points represent the fluorescence
across the nucleus. The different panels represent different time durations of hydrogen peroxide
stimulation or the lack there of; the top panel is 20 minutes, the middle panel is 10 minutes, and the
bottom panel is 5 minutes. The +/- denotes whether there was hydrogen peroxide stimulation (+) or a
control water stimulation (-). All of the plots on the left are WT cells, while the right are Y7F cells.
Next, as proof that the images I took were through the center of the cell in the z-plane, I also made plots
of z-stacks of DCBLD2-mCherry WT cells seen in Figure 26. The top of the cell had an oscillating
intensity from 20% to 40%. The stack that was taken 25% of the way down the cell was more similar to
previous plots with a peak around the membrane at 50% and only 20% intensity in the nuclear area. Halfway through the cells showed peaks around 50-55% around the membrane and 20% in the nuclear region.
75% of the way through the cell, there was a peak around 40% at the membrane and around 30% in the
nucleus. Finally, the bottom of the cell stack showed a relative flat intensity around 30%. This proved that
my images that were used for all previous plots were taken through the middle of the cell.
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Figure 26. My previous images were captured near the middle z-plane of the HEK293 cells. The
control plots of 5 DCBLD2-mCherry fusion transfected WT cells that show that the images I captured and
used for the previous plots were from the middle z-plane of the cells. These plots were of distance versus
intensity with a line that fits to the mean and standard deviation error bars. Each plot is labelled as either
being the top of the cell, 25% of the way down the cell, 50% or the middle of the cell, 75% of the way
down the cell, and the bottom of the cell.
All of these plots were not enough evidence to determine localization differences without any statistical
data analysis. Therefore, the plots were fitted to quadratic equations to directly compare the difference in
localization. I used equation-based statistical tests to see if DCBLD2 WT and Y7F or DCBLD2 WT and
PlxnA2 WT showed localization differences. I used a statistical analysis of the second order polynomial
equations from 1 micron to 15 microns across the cell (the hyperbolic portion of the data) to see if the
parameters were similar or different. The DCBLD2 WT and Y7F were statistically significantly different
between equations for the lines fitted to the data sets (p<0.0001).
Also, the DCBLD2 WT and PlxnA2 WT graphs were statistically significantly different based on the best
fitting lines (p<0.0001). The quadratic term of the equation represents the magnitude of the change in
slope of the curve. From highest to lowest in regards to the quadratic term were: DCBLD2 Y7F,
DCBLD2 WT, and then PlexinA2 WT (0.009936, 0.007562, 0.006991). The linear term represented the
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turning point of the parabola (along with the quadratic term). These were fairly similar for the three
proteins. The numerical term described where the height of the parabola intersected the y-axis. The
highest intensity on the edge was seen in the DCBLD2 Y7F cells and the lowest was in PlexinA2 WT
cells. Therefore, the major differences were in the quadratic and numerical terms for the proteins, which
are seen in Figure 27. The equations were statistically significantly different between all three proteins,
which means that the three proteins all have different subcellular localizations.

Figure 27. DCBLD2 WT, DCBLD2 Y7F, and PlxnA2 WT are localized differently in HEK293 cells.
The graph plots the statistically significantly different quadratic equations for DCBLD2 WT, DCBLD2
Y7F, and PlxnA2 WT. The graph was constructed with the fitted quadratic equations to the data sets for
DCBLD2 WT mCherry fusion transfected cells (red), DCBLD2 Y7F mCherry transfected cells (blue),
and PlexinA2 WT Flag-tagged transfected cells (green) (“Desmos Graphing Calculator”). The line was
fitted to extend from 1 micron to 15 microns, which were the hyperbolic portions of the previous plots.
The plotted lines were all statistically significantly different from one another.
Next, the same quadratic equations were fitted to the stimulated DCBLD2 WT and Y7F cell data. For the
twenty minute stimulation, the statistically significant differences were between the numerical and linear
terms between the wild type and the mutant when stimulated. DCBLD2 WT was more concentrated at the
membrane, but there was no difference between the fluorescence intensity change across the cell
(quadratic term). And there was no statistically significant difference between stimulated or un-stimulated
cells.
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For the ten minute stimulation, the statistically significant differences were between the DCBLD2 WT
stimulated and unstimulated cells. The unstimulated cells were more concentrated at the membrane based
on the numerical and linear terms of the quadratic equation. The other significant differences were
between the unstimulated DCBLD2 WT and Y7F cells in all terms of the equation. The WT cells were
more concentrated at the membrane and had a greater fluorescence intensity slope change from the
membrane to the middle of the cell.
For the five minute stimulation, the statistically significant differences were between the DCBLD2 WT
stimulated and unstimulated cells in the quadratic and numerical terms. DCBLD2 WT stimulated was
more concentrated at the membrane and had a larger fluorescence slope change. The other significant
differences were between the unstimulated DCBLD2 WT and Y7F cells in all terms of the equation.
DCBLD2 Y7F was more concentrated at the membrane and had a higher slope change than DCBLD2
WT. All of these quadratic equations can be seen in Figure 28.
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Figure 28. Hydrogen peroxide-induced phosphorylation plays a role in localizing DCBLD2 WT.
The graphs of the best fitted quadratic equations for the three stimulation treatment groups illustrates
opposing statistical significant differences between stimulation time lengths. The top left graph is twenty
minutes, the top right is ten minutes, and the bottom is the five minute stimulation. The lines represent the
DCBLD2 WT mCherry fusion transfected cells with hydrogen peroxide (red), DCBLD2 WT mCherry
fusion transfected cells without hydrogen peroxide (blue), DCBLD2 Y7F mCherry fusion transfected
cells with hydrogen peroxide (green), and DCBLD2 Y7F mCherry transfected cells without hydrogen
peroxide (yellow). The line was fitted to extend from 1 micron to 15 microns, which were the hyperbolic
portions of the original plots. The
represents statistically significant differences between DCBLD2
WT and Y7F mCherry fusion localization patterning. The * represents statistically significant differences
between DCBLD2 WT localization with and without hydrogen peroxide stimulation.
The final statistical test I used to try see if DCBLD2 is located primarily at the cell membrane was a t-test
to see if the DCBLD2 mCherry fluorescence weakened as it moved further from the cell membrane and
closer to the nucleus. This was measured for DCBLD2 WT and Y7F and PlxnA2 WT proteins. The
results were all statistically significant that the fluorescence intensity decreased the further from the cell
membrane it was measured (DCBLD2 WT p=0.0045, DCBLD2 Y7F p=0.0037, PlxnA2 WT p<0.0001).
The results can be seen in Figure 29. This shows that DCBLD2 WT and Y7F and PlxnA2 proteins have a
stronger intensity at the membrane than as we go further into the cell’s cytoplasm measured with just a
0.75 micron distance from the membrane.
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Figure 29. DCBLD2 WT, DCBLD2 Y7F, and PlxnA2 WT are localized at the plasma membrane.
The box-and-whisker plots of DCBLD2 WT mCherry and Y7F mCherry fusion transfected cells and
PlxnA2 WT Flag-tagged transfected cells revealed that the fluorescence of all three proteins is statistically
significantly higher at the membrane and lowers as we move further through the cytoplasm towards to the
middle of the cells. The plots represent the fluorescence intensity as I measured from the peak intensity at
the cell membrane and then the inward cytoplasmic portion towards the nucleus (same data used for all
previous plots). The membrane measurements were taken from 1-1.75 microns and 14.25-15 microns,
while the cytoplasmic region near the nucleus measurements were right next to these from 1.75-2.5
microns and 13.5-14.25.
Discussion
My overall goal was to determine if DCBLD2 localized similarly to the plasma membrane like PlxnA2
and NP-1. DCBLD2 is a scaffold protein for CrkL. DCBLD2 has its ectodomains clustered, which allows
SFKs to activate each other at its tyrosine residues. This general idea of how it functions leads us to
believe that DCBLD2 should be located near the membrane so CrkL can bind and the clustering can
occur intracellularly. Therefore, I hypothesized that it is localized at the plasma membrane like PlxnA2
and NP-1. These proteins share similar domains that target them for the cell membrane.
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Bioinformatics searches on these three proteins concurred with my hypothesis. PlxnA2 was predicted to
have signal peptide, transmembrane helices, be cytoplasmic, and can possibly be secreted. NP-1 and
DCBLD2 were found to have signal peptides, have transmembrane helices, and can possibly be secreted.
These results show that the three proteins have a signal peptide, demonstrate the ability to be
transmembrane, and are targeted for the cell membrane (possible secretion). Next, these predictions had
to be tested for accuracy.
My first step was to create the different DNA constructs to further study the localization of DCBLD2 WT
and Y7F. This was successfully completed as seen through test-cuts, Western blots, and DNA sequencing
of the plasmids. After the constructs were made, they were transfected into cells, underwent the
immunofluorescence procedure, and were imaged via the confocal microscope. The first cells imaged
were the DCBLD2 Flag-tagged constructs. These images had few cells that were successfully transfected
and the fluorescence was dim. This could be from the permeant that was only used in the Flag-tagged
construct procedure. The permeant puts holes in the plasma membrane so that the antibody can enter the
cells.
In regards to the DCBLD2 IRES-mCherry constructs, the images revealed that Flag-tagging the DCBLD2
had not altered its ability to express in cells. The IRES-mCherry was upstream of the DCBLD2 sequence;
therefore, if the mCherry sequence was translated, then the DCBLD2 was most likely translated as well
(Valerius, n.d.). Since expression was seen in the DCBLD2 IRES-mCherry constructs similarly to the
DCBLD2 Flag-tagged original constructs, we can assume that the Flag-tag did not disrupt the targeting of
the DCBLD2 protein. We could also see from bright field images that cells that were transfected with the
DCBLD2 IRES-mCherry constructs were not differently sized or shaped than their un-transfected
neighboring cells. Therefore, DCBLD2 IRES-mCherry was not a hindrance to the HEK293 cells.
Next, the DCBLD2-mCherry fusion constructs were created and showed the best expression pattern
compared to the previous two constructs. This construct was hence chosen for all of the confocal imaging
and data collection and analysis. The DCBLD2 WT and Y7F mCherry-fusion constructs were very
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similar in subcellular localization based on the immunofluorescent images themselves. They both
appeared to be situated at the membrane, which matches the bioinformatics prediction program for
DCBLD2. DCBLD2 has transmembrane domains, therefore it should be targeted and trafficked away
from and towards the membrane.
Through the data analysis of the fluorescence intensity of the DCBLD2-mCherry fusion protein, the graph
created made it unclear whether the protein was definitely at the membrane or if it was just a non-nuclear
protein. The fluorescence intensity was then compared right at the cell membrane compared to in the
cytoplasm before the nucleus started. This showed that there was a graded decrease in DCBLD2 as we
progressed from the cell membrane to the middle of the cell. The t-test run on this data revealed that there
was statistically significantly more fluorescence near the membrane compared to the cytoplasm near the
nucleus. This was also true for PlxnA2 data. These results inferred that the proteins were located at the
plasma membrane more than in the general cytoplasm or the nucleus.
The second part of my hypothesis was to show that DCBLD2 Y7F was not as or more concentrated at the
membrane as DCBLD2 WT. DCBLD2 Y7F is missing its tyrosine motifs, so it cannot be phosphorylated
by the SFKs and cause signaling when CrkL binds. If it cannot perform its normal proposed adaptor
function, then the mutant form should not be trafficked as heavily towards or away from the membrane as
the wild-type is. The fluorescence intensity data did show a statistically significant difference between the
patterns of fluorescence intensity across the cells. It showed that DCBLD2 Y7F started out with the
higher intensity at the edge of the plasma membrane and the slope of the fluorescence change was larger.
This revealed that DCBLD2 Y7F was more concentrated at the plasma membrane than DCBLD2 WT.
This could be due to the Y7F not being internalized since it cannot be phosphorylated. This would be true
if phosphorylation caused DCBLD2 WT to be internalized into the cell from the plasma membrane.
Next, I stimulated the two constructs with hydrogen peroxide to cause phosphorylation by stopping
phosphatases from removing phosphates. Once the DCBLD2 was phosphorylated, it might have been
internalized and trafficked inwardly. I wanted to see if there was a difference in trafficking in the wild-
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type and mutant constructs when stimulated. This did not show a definitive difference in the localization
of the two proteins.
The stimulation experiments show that there might be an affect by stimulation for the ten and five minute
stimulations on the DCBLD2 WT cells. The stimulated proteins were more concentrated at the membrane
in the five minute stimulation, but less at the membrane in the ten minute stimulation. These were
opposing results. What I will conclude from this is that DCBLD2 Y7F localization was not affected by
hydrogen peroxide stimulation. This conclusion makes sense, since the Y7F protein lacks the seven YxxP
sites and cannot be phosphorylated, so it should not traffick any differently whether stimulated or
unstimulated.
The stimulation experiments showed some differences between localization of the DCBLD2 WT and Y7F
proteins. In the twenty minute stimulation, the stimulated WT cells were more concentrated at the
membrane than the Y7F cells. In the ten minute stimulation, the unstimulated WT cells were more
concentrated at the membrane and had a larger slope change across the cell than Y7F cells, while the
opposite was seen in five minute stimulated cells. This was more contrary evidence. It showed a flipflopping between whether the Y7F or WT was more concentrated at the membrane and how the intensity
changed across the cells.
The lack of difference and the many contradictions between the timed hydrogen peroxide stimulations is
most likely due to the fact that hydrogen peroxide was not specific at only stimulating/clustering
DCBLD2. Hydrogen peroxide stimulated the whole cell, and therefore, all of the proteins inside of it.
Hydrogen peroxide at high concentrations can also cause de-phosphorylation and would not show normal
trafficking of proteins (Veal, Day, & Morgan, 2007). The best method to study the stimulation/clustering
of DBCLD2 would be to use an antibody to cluster the DCBLD2. This clustering should allow signaling
and would cause DCBLD2 to be trafficked back inside of the cell if phosphorylation causes
internalization of DCBLD2.
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Lastly, I compared DCBLD2 WT and PlxnA2 WT localization, since my hypothesis had been that the
two proteins should have similar localization patterns. Both proteins were statistically significantly
localized at the membrane compared to the more cytoplasmic and nuclear portions of the cell as seen via
the t-test. Based on immunofluorescence images alone, both proteins were visually similar in localization.
But PlxnA2 WT was shown to be statistically significantly localized differently by having less
fluorescence intensity at the plasma membrane and a smaller decreasing slope in fluorescence. This could
just be due to PlxnA2 WT images having less background fluorescence than the DCBLD2 WT images.
Or it could mean that PlxnA2 WT was less represented specifically at the plasma membrane and is seen
more in the cytoplasm than DCBLD2, which shows a greater decrease in fluorescence intensity from the
membrane to the nucleus.
All in all, my results were not as expected. There was a difference between DCBLD2 WT and Y7F
subcellular localization, and there was a difference between DCBLD2 WT and PlxnA2 WT subcellular
localization. These results are important though, because now we can further understand that there are
differences in signaling based on a subcellular localization framework. In regards to what was statistically
significant, there was evidence was that DCBLD2 Y7F had more plasma membrane presence than
DCBLD2 WT in static, un-stimulated protocols, while DCBLD2 WT has more fluorescence surrounding
the membrane than PlxnA2 WT. This reveals that DCBLD2 is more concentrated around the membrane
than PlxnA2. This could demonstrate that PlxnA2 complexes are in the membrane and the cytoplasm and
are constantly, dynamically moving back and forth, while DCBLD2 is more strictly membranous. Lastly,
hydrogen peroxide stimulation of the DCBLD2 WT and Y7F did not show a clear unidirectional
difference between the localization of the two proteins. Therefore the presence or absence of the seven
YxxP sites accompanied by phosphorylation did not alter the trafficking of DCBLD2 in one specific way.
I would hypothesize that the mechanism of action of DCBLD2 may be more complex dependent on
phosphorylation length and what agent was causing the phosphorylation. My data and constructs can be
used for future experiments on DCBLD2.
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One future experiment can be to cluster the DCBLD2 using an antibody and see how clustering affects
the trafficking of the protein (Aten et al., 2013). DCBLD2 is part of the Src-family of tyrosine kinase
receptors. Once tyrosine kinase receptors are activated, they are internalized to allow signaling to
continue. Therefore, DCBLD2 might be internalized after stimulation. NP-1 has been shown to be
internalized after co-receptor, the VEGFR receptor, is phosphorylated. When the phosphorylation is
blocked, both the VEGFR receptor and Nrp-1 are not internalized (Prahst et al., 2008). Since DBCLD2 is
a neuropilin-like protein, then it should show a similar pattern of internalization when phosphorylated.
While the DCBLD2 Y7F will be unable to be phosphorylated and would not be internalized to allow
signaling.
Another experiment that can be done using the constructs is to put them into other cell types. Since
DCBLD2 is known to be involved in neuronal migration via Crk/CrkL binding. Therefore, the DCBLD2
protein would be best studied in neuronal cells that it would normally carry out its function in. There are
many different neuronal cell lines that can be used to study DCBLD2 (Wu et al., 1999) (Gordon, Amini,
& White, 2013). These might be better than studying it in human embryonic kidney cells where it is not
known to carry out its normal neuronal or vascular functions. The HEK cells also contain a very large
nucleus, leaving little room for cytoplasm before the plasma membrane emerges. The live imaging of
retinal ganglion cells with the DCBLD2 protein being fluorescently expressed would also allow the
visualization of the actual trafficking of the protein. Our collaborators at Boston College have been
working with Xenopus retinal ganglion cells for immunofluorescent protein trafficking for many years
(Álvarez-Hernán et al., 2013). The constructs I made were sent in mRNA form to them, so they can
follow the trafficking of DCBLD2 in live cells.
My constructs and the data collected from them can be useful in the future. But there are also other ways I
could have undertaken to find the subcellular localization of DCBLD2. If there are better ways to study
DCBLD2 localization, why did I choose HEK293 cells? These cells were accessible, convenient, and
relatively inexpensive to upkeep. The Ballif Lab has been transfecting HEK293 cells to study cell
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signaling for many years. The HEK293 cells transfect easily and enable the sample size to be large. HEK
cell lines are easy to upkeep, fold proteins accordingly, and have been used for over 35 years as a cell line
to use recombinant DNA in (Thomas & Smart, 2005).
Next, why did I choose immunofluorescence over a different procedure to find the localization of
DCBLD2? I chose to use immunofluorescence and confocal microscopy to study the subcellular
localization of DCBLD2, because I had access to a confocal microscope and the immunofluorescence
protocol results were reproducible. Immunofluorescence microscopy is a valid method to find the
localization of a protein, because it can give actual images of the protein and there are computer programs
to measure the fluorescence intensity across the cell. Immunofluorescent imaging has been used by many
research groups to approximate the localization of specific proteins (Stadler et al., 2013). These are the
reasons I chose to use immunofluorescence to find the localization over other methods. But, I do realize
there were other methods to figure this out.
One other way is to try to co-localize DCBLD2 with plasma membrane markers/proteins. The plasma
membrane markers/stains can be co-transfected with DCBLD2 DNA or there are stain versions. WGA
(wheat germ agglutinin) is a lectin marker for the plasma membrane that is conjugated with a fluorophore.
The WGA can be added to a cell culture to probe for the plasma membrane. Another marker is CellMask
stains. CellMask stains stain the plasma membrane for fluorescence microscopy. It exhibits no cell-type
specific plasma membrane staining, unlike WGA. Both markers only work on fixed, non-permeabilized
cells (Bononi & Pinton, 2015). If either marker is co-localized with DCBLD2, then DCBLD2 can be
considered localized to the plasma membrane. The two fluorescent dyes would need to be different colors
to show the overlap, or lack thereof.
Another method to find the subcellular localization is to fraction the cells into parts and western blot each
cell portion to see where DCBLD2 would be most concentrated. First, the cells would be cultured and
transfected, then they would undergo a long centrifugation technique to separate the cell components into
different tubes (Leslie et al., 2001). The different components that can be separated out are: nuclei,
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mitochondria, cytoplasm (with other soluble proteins and organelles), and plasma membrane
(“Subcellular fractionation protocol | Abcam”). Then, these tubes can be Western blotted using an antiDCBLD2 antibody to test the difference in DCBLD2 concentration in the four cell compartments.
Although there are other ways to study the subcellular localization of DCBLD2, I stand by my methods,
because they turned out valuable results. My methods allowed me to compare DCBLD2 to PlxnA2 WT’s
subcellular localization. DCBLD2 WT and Y7F and PlxnA2 WT were all found to be more concentrated
at the cell membrane than the cytoplasm or nucleus. DCBLD2 WT and PlxnA2 WT were similarly at the
membrane, but DCBLD2 had more presence in the plasma membrane than PlxnA2 did. DCBLD2 Y7F
was more heavily concentrated at the membrane than its WT counterpart. This could reveal that the seven
YxxP sites are integral in its subcellular localization. In conclusion, DCBLD2 appears to be trafficked to
the plasma membrane similarly to PlxnA2, but stays more concentrated around the membrane rather than
in the cytoplasm.
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Supplemental
Primers used to make mCherry insert for DCBLD2 mCherry-fusion protein:
Forwards Primer: 5’- GCAAAAACGCGTGGAATGGTGAGCAAGGGC – 3’
Reverse Primer: 5’- GGCGGCGTTTAAACTCTAGATTACTTGTACAGCTCGTCC – 3’
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